Publication digest
CDK4/6 inhibitors in combination with endocrine therapy as potential therapies for treating high-risk early breast cancer patients
Does addition of abemaciclib to endocrine therapy (ET) as an adjuvant treatment of HR+, HER2−, node-positive, high-risk, early breast cancer patients provide additional benefits versus treatment with ET alone?
Why sign up with Medthority?
Develop your knowledge with our disease and condition focused Learning Zones
Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines
Personalised dashboard providing updates and recommendations for content within your areas of interest
Developed by EPG Health for Medthority. This content has been developed independently of the sponsor Eli Lilly, who have had no editorial input into the content. EPG Health received unrestricted educational funding from the sponsor in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.